COHEN & STEERS INC (CNS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CNS - US19247A1007 - Common Stock
64.2 USD
+0.98 (+1.55%)
64.2 USD
0 (0%)
CNS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 238 industry peers in the Capital Markets industry. While CNS belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. CNS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CNS had positive earnings in the past year.
CNS had a negative operating cash flow in the past year.
In the past 5 years CNS has always been profitable.
Each year in the past 5 years CNS had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 20.48%, CNS belongs to the best of the industry, outperforming 97.90% of the companies in the same industry.
CNS has a better Return On Equity (29.83%) than 95.80% of its industry peers.
CNS has a Return On Invested Capital of 24.24%. This is amongst the best in the industry. CNS outperforms 98.32% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.00%.
The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(24.24%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROIC | 24.24% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
Looking at the Profit Margin, with a value of 29.73%, CNS is in the better half of the industry, outperforming 74.79% of the companies in the same industry.
In the last couple of years the Profit Margin of CNS has declined.
With a decent Operating Margin value of 33.83%, CNS is doing good in the industry, outperforming 65.55% of the companies in the same industry.
CNS's Operating Margin has declined in the last couple of years.
CNS's Gross Margin of 88.60% is amongst the best of the industry. CNS outperforms 92.86% of its industry peers.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
CNS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CNS has been increased compared to 5 years ago.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.90 indicates that CNS is not in any danger for bankruptcy at the moment.
CNS has a better Altman-Z score (8.90) than 93.28% of its industry peers.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.9 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNS has a Current Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS has a Current ratio of 0.79. This is in the lower half of the industry: CNS underperforms 63.45% of its industry peers.
A Quick Ratio of 0.79 indicates that CNS may have some problems paying its short term obligations.
CNS has a Quick ratio of 0.79. This is in the lower half of the industry: CNS underperforms 63.03% of its industry peers.
The current and quick ratio evaluation for CNS is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.87% over the past year.
The Earnings Per Share has been growing slightly by 2.50% on average over the past years.
Looking at the last year, CNS shows a quite strong growth in Revenue. The Revenue has grown by 11.13% in the last year.
Measured over the past years, CNS shows a small growth in Revenue. The Revenue has been growing by 4.72% on average per year.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
3.2 Future
The Earnings Per Share is expected to grow by 7.68% on average over the next years.
CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.21% yearly.
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.91, the valuation of CNS can be described as rather expensive.
The rest of the industry has a similar Price/Earnings ratio as CNS.
CNS is valuated rather cheaply when we compare the Price/Earnings ratio to 26.57, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 18.53, which indicates a rather expensive current valuation of CNS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CNS is on the same level as its industry peers.
CNS is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.91 | ||
| Fwd PE | 18.53 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than 79.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 15.77 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CNS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.58
PEG (5Y)8.37
EPS Next 2Y8.74%
EPS Next 3Y8.1%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.92%.
Compared to an average industry Dividend Yield of 6.54, CNS has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.00, CNS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.92% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
76.25% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
64.2
+0.98 (+1.55%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners58.72%
Inst Owner Change-5.95%
Ins Owners22.81%
Ins Owner Change3.24%
Market Cap3.27B
Revenue(TTM)552.10M
Net Income(TTM)164.16M
Analysts48
Price Target78.54 (22.34%)
Short Float %6.45%
Short Ratio4.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.92% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.71%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)2.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.91 | ||
| Fwd PE | 18.53 | ||
| P/S | 5.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.95 | ||
| P/tB | 6.18 | ||
| EV/EBITDA | 15.77 |
EPS(TTM)3.07
EY4.78%
EPS(NY)3.46
Fwd EY5.4%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.82
BVpS10.79
TBVpS10.39
PEG (NY)4.58
PEG (5Y)8.37
Graham Number27.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROCE | 31.59% | ||
| ROIC | 24.24% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 32.58% | ||
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 1.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 8.9 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
EBIT growth 1Y15.71%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year11.22%
EBIT Next 3Y14.28%
EBIT Next 5Y13.32%
FCF growth 1Y-175.84%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-150.56%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%
COHEN & STEERS INC / CNS FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CNS.
Can you provide the valuation status for COHEN & STEERS INC?
ChartMill assigns a valuation rating of 3 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
Can you provide the profitability details for COHEN & STEERS INC?
COHEN & STEERS INC (CNS) has a profitability rating of 8 / 10.
What are the PE and PB ratios of COHEN & STEERS INC (CNS) stock?
The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 20.91 and the Price/Book (PB) ratio is 5.95.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.